tbuckley/cabot-search huggingface dataset:
Central Park
Journal: JAMA Internal Medicine (2013)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Pharmacoeconomics: is a drug worth its cost?
Authors: C. Marwick
Journal: JAMA (1994)

THE PRICE is right, the cost is reasonable, but in tomorrow's medical practice what will count is the effectiveness of the intervention in relation to the cost of providing it. A whole new science is springing up that is engaged in developing appropriate standards and ways to evaluate such efficacy from a drug or medical service, say those in this emerging field of pharmacoeconomics. "You can bet your boots that in the next 4 or 5 years this is going to be a major issue because it has to do with health reform and cost control efforts," says Clyde Thornsberry, PhD, of the Microbiology Reference Library, Franklin, Tenn. Thornsberry spoke at the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, held in Orlando, Fla. At future meetings the group plans to hold more sessions on cost-effectiveness studies. <h3>`Where the Money Is'</h3> At the moment, the effort is limited largely to
Individualized treatment with sunitinib versus standard dosing with sunitinib or pazopanib in patients with metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis).
Authors: Naveen S. Basappa, Aly-Khan A. Lalani, Austin Kalirai, Haocheng Li, Lori Wood, Christian K. Kollmannsberger, Hao-Wen Sim, Anil Kapoor, Sebastien J. Hotte, Piotr Czaykowski, Christina M. Canil, M. Neil Reaume, Georg A. Bjarnason, Marie Vanhuyse, Denis Soulieres, Scott A. North, Daniel Yick Chin Heng
Journal: Journal of Clinical Oncology (2017)

e16078 Background: Recent analysis using CKCis showed that mRCC patients receiving first-line sunitinib (S) had better survival than patients receiving pazopanib (P) and greater than expected survival for a real world sampling. We conducted further analyses to see if an individualized approach (treatment starting at standard dose/schedule with subsequent schedule/dose alterations based on toxicity) using S results in better outcomes in mRCC patients. Methods: Patients within CKCis diagnosed with clear cell mRCC treated with first-line S or P between January 2011 through December 2015 were analyzed by three treatment groups: 1) S as per individualized approach (SI) 2) S as per product monograph (SS) 3) P as per product monograph (PS). Overall survival (OS) and time-to-treatment failure (TTF) were calculated. Cox regression analysis allowed for adjustment of International Metastatic RCC Database Consortium (IMDC) criteria with age as a continuous variable. Results: A total of 598 patients were identified, 351 patients in SI, 151 patients in SS, and 92 patients in PS. Baseline characteristics are noted in Table 1. Median OS was improved in SI vs SS (37.9 vs 22.3 months (m), p&lt;0.001) and SI vs PS (37.9 vs 19.6 m, p&lt;0.001). TTF was better in SI vs SS (12.9 vs 5.6 m, p&lt;0.001) and SI vs PS (12.9 vs 7.0 m, p&lt;0.001). SS vs PS showed no difference in median OS (22.3 vs 19.6 m, p=0.51) or TTF (5.6 vs 7.0 m, p=0.24). Adjusted hazard ratios were: SS vs SI (OS 1.41, p=0.056; TTF 1.77, p&lt;0.001) and PS vs SI (OS 2.18, p&lt;0.001; TTF 1.43, p=0.040). Conclusions: Improvement in OS and TTF is seen using an individualized approach to mRCC patients supporting the growing body of evidence endorsing this practice. Further prospective validation awaits the NCT01499121 study. [Table: see text]
Human in vitro fertilization. A conservative view
Authors: H. O. Tiefel
Journal: JAMA (1982)

Ethical objections to both the means and ends of clinical in vitro fertilization and embryo transfer, as well as of nonclinical applications, are analyzed and evaluated. Morally important but inconclusive arguments consider these procedures to be unnatural or harmful to women. The decisive objection to clinical uses lies in the possible and even likely risk of greater than normal harm to offspring. A discussion of the need and right to have children, and of the relationship of this procedure to abortion and to freezing embryos, concludes the analysis of clinical uses. The ethics of research applications of in vitro fertilization hinges on the status of the embryo. After prefatory conceptual clarification, this article argues for the inclusion of human embryos within protectable humanity, which makes nontherapeutic research unjustifiable. Public decision making and federal research funding are discussed. (<i>JAMA</i>1982;247:3235-3242)
Big Things.
Authors: W. P. Howle
Journal: JAMA (1894)

<h3>To the Editor:</h3> —In a friendly chat with one of my medical friends, recently, I asked him why he did not take theJournal of the American Medical Association. His reply was as follows: "It is too full of<i>big things</i>." There is some truth in this assertion. TheJournalis often full of big things; my friend claims that the so-called expert and the specialist are allowed too much space in which to air themselves; that it requires too much effort upon the part of the country doctor to digest the "big things." He says the country doctor's time is better spent in reading a few practical<i>truths</i>than in trying to analyze a lengthy article on "Electro-anesthesia and Frequency of Induction Vibration;" "The Esoteric Beauty and Utility of the Microscope"; "Appendicitis with Original Report of One Hundred and Forty-one Histories and Laparatomies for that disease under Personal Observation."
John Braxton Hicks (1823-1897)
Journal: JAMA (1969)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
From the Food and Drug Administration
Authors: Stuart L. Nightingale
Journal: JAMA (1989)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Error in Key Points
Journal: JAMA Pediatrics (2018)

Andrea T. Cruz, MD, MPH; Prashant Mahajan, MD, MPH, MBA; Bema K. Bonsu, MB, ChB; Jonathan E. Bennett, MD; Deborah A. Levine, MD; Elizabeth R. Alpern, MD, MSCE; Lise E. Nigrovic, MD, MPH; Shireen M. Atabaki, MD, MPH; Daniel M. Cohen, MD; John M. VanBuren, PhD; Octavio Ramilo, MD; Nathan Kuppermann, MD, MPH; for the Febrile Infant Working Group of the Pediatric Emergency Care Applied Research Network
Fusobacterium Septicemia Following Human Bite
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Usefulness of HEVantigen determination in the diagnosis of acute hepatitis E
Authors: Victor J Beltrán, Cristian Castelló-Abietar, Pablo Florez Díez, Noelia Rodríguez Ferreiro, Ángela Suárez Noya, Alejandro Nieto Jara, Celia Del Caño Cerdán, Maria Luisa Gonzalez Dieguez, Mercedes Rodríguez, Carmen Álvarez-Navascués, Melón Santiago, Manuel Rodríguez
Journal: Journal of Hepatology (2020)
BIOCHEMISTRY IN THE UNITED STATES
Journal: JAMA (1931)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Proposed National Bureau of Medicines and Foods.
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Focal intracranial mucormycosis presenting as chronic meningitis
Authors: P. G. Jones
Journal: JAMA (1981)

INTRACRANIAL mucormycosis occurs almost exclusively in patients with predisposing diseases. The infection is usually a result of either direct intracranial invasion or hematogenous spread. Isolated intracranial infection is rarely seen. We describe an unusual case of focal intracranial mucormycosis, presenting as chronic meningitis of several months' duration. A parameningeal focus, osteomyelitis of the clivus, was ultimately discovered, and the patient was successfully treated with neurosurgery and amphotericin B. <h3>Report of a Case</h3> A 61-year-old maintenance man was seen in an emergency room for headache on March 8, 1979, and was found to have mild hyperglycemia. One week later, diplopia developed and he was consequently admitted to the Miriam Hospital, Providence, RI. Physical examination revealed an alert, well-oriented man complaining of severe headache. Neurological examination demonstrated a right lateral rectus paralysis but otherwise gave normal results. The neck was supple. Serum glucose concentration was 286 mg/dL. There was no ketoacidosis. The
Popsicle Panniculitis
Authors: Ervin H. Epstein, Mark E. Oren
Journal: New England Journal of Medicine (1970)

A RED nodule on an infants face may provoke mutilating or potentially dangerous intervention such as biopsy or antibiotic administration. This report describes a rarely recognized but probably quite common and benign cause of such a lesion.Case ReportAt the age of 12 weeks, this infant's weight and height were above the 90th percentile; she subsequently drank low-fat milk.At 6 months of age, a deeply situated, movable, firm, slightly elevated, warm red nodule 2 cm in diameter on the right cheek, adjacent to the mouth, developed over 24 hours (Fig. 1). There was no fever or palpable lymph-node . . .
Fixing Medicare
Authors: Marcia Angell
Journal: New England Journal of Medicine (1997)

Medicare costs are a major concern of Congress these days, and it is easy to see why. This program accounts for about 20 percent of personal health care expenditures in the United States and 11 percent of the federal budget.1,2 Policy makers are worried not so much about the absolute costs as about the rate of increase. Medicare inflation has consistently outstripped the consumer price index, averaging about 10 percent per beneficiary annually since 1969.2 Adding to the problem is the steady growth in the number of beneficiaries. As we are frequently reminded by the media, Medicare Part A's . . .
Postgraduate Haematology
Authors: Paulette Mehta
Journal: JAMA (2011)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Plasma fractionation in the United States. A review for clinicians
Authors: P. M. Ness
Journal: JAMA (1974)

The Cohn cold ethanol plasma fractionation system, developed in the late 1940s, is still the basis for plasma fractionation practices in the United States today. Plasma is obtained by plasmapheresis, salvaged from fresh or outdated whole blood, or is extracted from human placentas to produce five types of clinical products of proven efficacy and safety. Despite the recognized advantages and current entrenchment of the Cohn fractionation system and its partial solution of the hepatitis problem, new developments could improve the present practice. Improved salvage of useful proteins from fractions that are currently discarded must be strongly supported. (<i>JAMA</i>230:247-250, 1974)
Genetic screening in hypertrophic cardiomyopathy: Most beta-myosin mutations that are identified are novel with undefined clinical outcomes Saidi A. Mohiddin, Judith Winkler, Elisha MClam, David A. Begley, Lameh Fananapazir. NHLBI, National Institutes of Health, Bethesda, MD
Journal: Journal of the American College of Cardiology (2001)
The primary analysis of a phase I/IIa dose finding trial of a folate binding protein vaccine, E39 + GM-CSF in ovarian and endometrial cancer patients to prevent recurrence.
Authors: Doreen O Jackson, Timothy J. Vreeland, Julia M. Greene, Diane F. Hale, Erika J Schneble, John S. Berry, Alfred F. Trappey, Mark O Hardin, Guy T. Clifton, John Elkas, Chad Hamilton, Kathleen M. Darcy, George Larry Maxwell, George Earl Peoples
Journal: Journal of Clinical Oncology (2016)

5576 Background: Folate binding protein (FBP) is an immunogenic protein over-expressed in serous endometrial (EC) and ovarian cancer (OC). We’ve conducted a phase I/IIa trial using E39 (GALE-301, FBP 191-199, EIWTHSYKV), an HLA-A2-restricted, FBP-derived peptide, + GM-CSF to prevent recurrence in EC and OC patients(pts) after completion of standard of care(SOC) treatment. Here, we present the primary endpoints of the trial of safety, immune response and 2-yr disease-free survival (DFS). Methods: This trial began as a dose-escalation trial and transitioned to a phase IIa comparing expanded dose cohorts. Disease-free EC and OC pts were enrolled after SOC. HLA-A2+ pts were vaccinated (VG), and HLA-A2- pts followed as a control group (CG). The VG received 6 monthly inoculations of E39 + 250 mcg GM-CSF as the primary vaccination series (PVS) followed by two boosters every 6mo. Of 29 vaccinated pts, 24 completed the PVS, 17 received one booster and 14 received two. Demographic, safety, immunologic, and recurrence data were analyzed using the appropriate statistical tests. Results: 51 pts were enrolled (29 in VG, 22 in CG). 15 pts received 1000mcg, the optimal dose, during PVS (OPT), and 14 < 1000mcg (nOPT). There were no demographic differences between groups. All doses were safe with no > grade 3 toxicities. DTH increased pre- to post-PVS (5.9+1.5 mm v 11.7+3.2 mm, p= 0.07) with larger increase in OPT pts (3.8+2.0 mm v 9.5+3.5 mm, p= 0.07) v nOPT (7.8+2.1 mm v 11+5.0 mm, p= 0.24). After a median follow-up of 16mo, the overall recurrence rate(RR) was 44.8% in the VG v 54.5% in CG (p= 0.58). Though influenced by survival bias, the RR was only 23.5% in boosted pts. The estimated 2-yr DFS was 41.4% in VG v 36% in CG (p= 0.70); however, in the OPT group, the 2-yr DFS was 64.3% v 36% in the CG (p= 0.03). Conclusions: This phase I/IIa trial utilizing E39 and booster inoculations to prevent recurrence in EC and OC pts has shown the vaccine to be safe and immunogenic. These results demonstrate the potential clinical benefit of E39 at the 1000mcg dose to prevent recurrence and that boosters may sustain this effect. These promising results will be further evaluated in a larger clinical trial. Clinical trial information: NCT01580696.
Clinical experience with the oxygen concentrator
Authors: P Howard
Journal: BMJ (1983)

The oxygen concentrator is an accepted means of delivery of long term domiciliary oxygen treatment.Conditions of use, however, need to be carefully defined.Fourteen concentrators were used for one year by patients with hypoxaemic chronic obstructive airways disease, and mechanical reliability, patient compliance with a regimen of 15 hours' use a day, smoking habits, and variation in arterial gas tensions studied.Though many patients failed to achieve either the desired daily use or the recommended arterial oxygen tension, problems were generally minor and could probably be overcome by careful supervision and planning.Overall the concentrator appeared to be the most econo- mical means of providing oxygen treatment at home and was much preferred by patients who had previously used oxygen cylinders.
USSR
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal